Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors

The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier es...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2018-01, Vol.38 (1), p.359-365
Main Authors: Chrom, Pawel, Stec, Rafal, Bodnar, Lubomir, Szczylik, Cezary
Format: Article
Language:English
Subjects:
Cell survival
Hazards
Health risk assessment
Inhibitors
Kidney cancer
Metastases
Metastasis
Pancreas
Patients
Rank tests
Regression analysis
Renal cell carcinoma
Tyrosine
Tyrosine kinase inhibitors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c372t-58206e34736b8d042b141f2ddf798e3b415477db91f2f525dcc5c686317bd5d33
cites
container_end_page 365
container_issue 1
container_start_page 359
container_title Anticancer research
container_volume 38
creator Chrom, Pawel
Stec, Rafal
Bodnar, Lubomir
Szczylik, Cezary
description The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR). Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098). The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease.
doi_str_mv 10.21873/anticanres.12230
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1980542511</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1980542511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-58206e34736b8d042b141f2ddf798e3b415477db91f2f525dcc5c686317bd5d33</originalsourceid><addsrcrecordid>eNpdkUlLBDEQhYMoOi4_wIsEvHhpzdLppI8yuKHioOO5SSfVGplONOlB5uJvN-O4gBAqReq9jxQPoX1KjhlVkp9oPzijfYR0TBnjZA2NqKxpIQUn62hEmCCFJERsoe2UXgipqlrxTbTFaialrMUIfUxiePIhZQ5-cE_edUugARw6PMlNBL0c3cKgUz6QcBdDj-_B6xkewywXHY3zodfY-WwZHPgh4enSCBa_u-EZTxcxJOcBXzufGfjKP7vWDSGmXbTR6VmCve97Bz2en03Hl8XN3cXV-PSmMFyyoRCKkQp4KXnVKktK1tKSdszaTtYKeFtSUUpp2zo_doIJa4wwlao4la0VlvMddLTivsbwNoc0NL1LJn9fewjz1NBaEVEyQWmWHv6TvoR5zOumhlGuKiKYWgLpSmXyailC17xG1-u4aChpvsJp_sJpvsLJnoNv8rztwf46ftLgn3SMjgc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138605283</pqid></control><display><type>article</type><title>Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Chrom, Pawel ; Stec, Rafal ; Bodnar, Lubomir ; Szczylik, Cezary</creator><creatorcontrib>Chrom, Pawel ; Stec, Rafal ; Bodnar, Lubomir ; Szczylik, Cezary</creatorcontrib><description>The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR). Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098). The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.12230</identifier><identifier>PMID: 29277795</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Cell survival ; Hazards ; Health risk assessment ; Inhibitors ; Kidney cancer ; Metastases ; Metastasis ; Pancreas ; Patients ; Rank tests ; Regression analysis ; Renal cell carcinoma ; Tyrosine ; Tyrosine kinase inhibitors</subject><ispartof>Anticancer research, 2018-01, Vol.38 (1), p.359-365</ispartof><rights>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright International Institute of Anticancer Research Jan 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-58206e34736b8d042b141f2ddf798e3b415477db91f2f525dcc5c686317bd5d33</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29277795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chrom, Pawel</creatorcontrib><creatorcontrib>Stec, Rafal</creatorcontrib><creatorcontrib>Bodnar, Lubomir</creatorcontrib><creatorcontrib>Szczylik, Cezary</creatorcontrib><title>Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR). Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098). The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease.</description><subject>Cell survival</subject><subject>Hazards</subject><subject>Health risk assessment</subject><subject>Inhibitors</subject><subject>Kidney cancer</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Pancreas</subject><subject>Patients</subject><subject>Rank tests</subject><subject>Regression analysis</subject><subject>Renal cell carcinoma</subject><subject>Tyrosine</subject><subject>Tyrosine kinase inhibitors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkUlLBDEQhYMoOi4_wIsEvHhpzdLppI8yuKHioOO5SSfVGplONOlB5uJvN-O4gBAqReq9jxQPoX1KjhlVkp9oPzijfYR0TBnjZA2NqKxpIQUn62hEmCCFJERsoe2UXgipqlrxTbTFaialrMUIfUxiePIhZQ5-cE_edUugARw6PMlNBL0c3cKgUz6QcBdDj-_B6xkewywXHY3zodfY-WwZHPgh4enSCBa_u-EZTxcxJOcBXzufGfjKP7vWDSGmXbTR6VmCve97Bz2en03Hl8XN3cXV-PSmMFyyoRCKkQp4KXnVKktK1tKSdszaTtYKeFtSUUpp2zo_doIJa4wwlao4la0VlvMddLTivsbwNoc0NL1LJn9fewjz1NBaEVEyQWmWHv6TvoR5zOumhlGuKiKYWgLpSmXyailC17xG1-u4aChpvsJp_sJpvsLJnoNv8rztwf46ftLgn3SMjgc</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Chrom, Pawel</creator><creator>Stec, Rafal</creator><creator>Bodnar, Lubomir</creator><creator>Szczylik, Cezary</creator><general>International Institute of Anticancer Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180101</creationdate><title>Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors</title><author>Chrom, Pawel ; Stec, Rafal ; Bodnar, Lubomir ; Szczylik, Cezary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-58206e34736b8d042b141f2ddf798e3b415477db91f2f525dcc5c686317bd5d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Cell survival</topic><topic>Hazards</topic><topic>Health risk assessment</topic><topic>Inhibitors</topic><topic>Kidney cancer</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Pancreas</topic><topic>Patients</topic><topic>Rank tests</topic><topic>Regression analysis</topic><topic>Renal cell carcinoma</topic><topic>Tyrosine</topic><topic>Tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chrom, Pawel</creatorcontrib><creatorcontrib>Stec, Rafal</creatorcontrib><creatorcontrib>Bodnar, Lubomir</creatorcontrib><creatorcontrib>Szczylik, Cezary</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chrom, Pawel</au><au>Stec, Rafal</au><au>Bodnar, Lubomir</au><au>Szczylik, Cezary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>38</volume><issue>1</issue><spage>359</spage><epage>365</epage><pages>359-365</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR). Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098). The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>29277795</pmid><doi>10.21873/anticanres.12230</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0250-7005
ispartof Anticancer research, 2018-01, Vol.38 (1), p.359-365
issn 0250-7005
1791-7530
language eng
recordid cdi_proquest_miscellaneous_1980542511
source EZB-FREE-00999 freely available EZB journals
subjects Cell survival
Hazards
Health risk assessment
Inhibitors
Kidney cancer
Metastases
Metastasis
Pancreas
Patients
Rank tests
Regression analysis
Renal cell carcinoma
Tyrosine
Tyrosine kinase inhibitors
title Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A44%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Significance%20of%20Pancreatic%20Metastases%20from%20Renal%20Cell%20Carcinoma%20in%20Patients%20Treated%20with%20Tyrosine%20Kinase%20Inhibitors&rft.jtitle=Anticancer%20research&rft.au=Chrom,%20Pawel&rft.date=2018-01-01&rft.volume=38&rft.issue=1&rft.spage=359&rft.epage=365&rft.pages=359-365&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.12230&rft_dat=%3Cproquest_cross%3E1980542511%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-58206e34736b8d042b141f2ddf798e3b415477db91f2f525dcc5c686317bd5d33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2138605283&rft_id=info:pmid/29277795&rfr_iscdi=true